Administrative Core

行政核心

• 批准号: 10259873
• 负责人: Kevin D Cooper
• 金额: $ 33.14万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-20 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10259873
• 关键词: Accountability; Achievement; Advisory Committees; Area; Artificial Intelligence; Bioinformatics; Clinical Data; Clinical Research; Communities; Computational algorithm; Computerized Medical Record; Core Facility; Cutaneous; Data; Data Set; Databases; Dermatology; Development; Electronic Health Record; Environment; Goals; Health Care Research; Healthcare; Healthcare Systems; Hospitals; Human; Human Experimentation; Infrastructure; Leadership; Machine Learning; Medical center; Methodology; Mission; Modeling; Mus; Pathway interactions; Patients; Pharmaceutical Preparations; Pre-Clinical Model; Process; Provider; Psoriasis; Research; Research Personnel; Research Project Grants; Resources; Role; Scientist; System; Talents; Techniques; Technology; Testing; Translating; Translational Research; University Hospitals; Unmarried person; Validation; Work; clinical application; clinical phenotype; cohort; comorbidity; data mining; decision making algorithm; design; experience; individual patient; innovation; innovative technologies; new technology; novel; programs; recruit; symposium

The mission of the CORT is to advance therapy for psoriasis and related comorbidities by leveraging new bioinformatic methodologies with well-developed murine and human experimentation capabilities. This technology concatenation is expected to more nimbly translate new scientific opportunities into clinical applications. The CORT Administrative Core (AC) proposes to manage an innovative model wherein a collaborative research project (CRP) will serve as the central hub that will iterate significant bi-directional work from 2 highly interactive research cores to experimentally test hypotheses and newly identified pathway specific and repurposed FDA drug leads. The AC will accomplish this goal through its Aims to: 1. Convene an Internal Advisory Committee and an External Advisory Board which a) develops and applies accountability metrics for the CRP, each Core, and the P&F projects, b) manages a Go-NoGo iterative algorithmic decision-making process regarding CORT resource utilization and c) coordinates patient cohort assets and regulatory compliance; 2. Provide fiscal management of the CORT; 3. Branch out exciting new developments deriving from CORT findings through a robust Pilot & Feasibility (P&F) program; 4. Organize and advertise Enrichment Activities that bring CORT and Community researchers together in scientific venues to exchange ideas and new technologies. The AC leadership will work closely not only with lab scientists, but also with the leadership and programmers of the CLEveland Area Research Platform for Advancing Translational Healthcare (CLEARPATH), a comprehensive research database with Limited Data Set contribution from all 3 major Cleveland healthcare systems. CLEARPATH will create connected data (e.g., Biospecimen results, EMR clinical phenotype, `Omics data) as well as a Single person record across the system, enabling research cohort discovery and validation across the aggregate dataset. This approach will allow us to preliminarily validate psoriasis cohort subsets, mix `omic pathways and drug leads identified by the Cores and CRP. In addition to its roles as an information conduit and facilitator for research, the AC also promotes the cutaneous research environment for psoriasis and its comorbid and related conditions through enrichment programs. As such, the AC is instrumental in the design and planning of research symposia, and recruiting potential P&F program recipients with innovative technologies and/or complementary research expertise to the CORT. The cross-disciplinary approach of combining a Preclinical Modeling Core (PMC) with an Applied Meta `Omics Core (AMC) that takes advantage of artificial intelligence, data mining, network techniques and machine learning to query available interaction networks and highly annotated integrated electronic medical records (EMRi) is highly innovative. The active engagement of the AC will be instrumental for the successful achievement of the broader goal of identifying new psoriasis pathways and repurposed approved drugs.

CORT的使命是通过利用新的 具有良好的小鼠和人体实验能力的生物信息学方法。这 技术串联有望更灵活地将新的科学机会转化为临床机会 申请。CORT管理核心(AC)建议管理创新模式，其中 协作研究项目(CRP)将成为重要的双向迭代的中心枢纽 从两个高度互动的研究核心到实验测试假说和新确定的 途径特定的和重新调整用途的FDA药物线索。咨询委员会将通过其目标来实现这一目标：1. 召集一个内部咨询委员会和一个外部咨询委员会，a)制定和应用 C-P、每个核心和P&F项目的责任指标，b)管理Go-NoGo迭代 关于CORT资源利用和c)协调患者队列的算法决策过程 资产和监管合规性；2.提供CORT的财务管理；3.拓展令人兴奋的新业务 通过强有力的试点和可行性(P&F)计划从CORT调查结果中得出的发展；4.组织 并宣传将CORT和社区研究人员聚集在科学场所的丰富活动 交流思想和新技术。 交流领导层不仅将与实验室科学家密切合作，还将与领导层和 克利夫兰地区促进转化性医疗研究平台的程序员 (ClearPath)，这是一个综合的研究数据库，所有三个主要数据库的数据集贡献都有限 克利夫兰医疗保健系统。ClearPath将创建连接的数据(例如，Biospecimen结果、EMR 临床表型、‘OMICS数据’)以及整个系统中的单个人记录，从而实现研究队列 跨聚合数据集的发现和验证。这种方法将使我们能够初步验证 由核心和C反应蛋白确定的银屑病队列亚群、混合的组途径和药物导联。除了……之外 作为研究的信息渠道和促进者，AC也促进了皮肤研究 牛皮癣及其共病和相关疾病的环境通过富营养化计划。因此， AC在设计和规划研究研讨会以及招募潜在的P&F计划方面发挥了重要作用 具有创新技术和/或补充CORT研究专业知识的获奖者。 结合临床前建模核心(PMC)和应用元的跨学科方法 ‘Omics Core(AMC)，它利用人工智能、数据挖掘、网络技术和 用于查询可用交互网络和高度注释的集成电子医疗的机器学习 记录(EMRI)具有很高的创新性。AC的积极参与将有助于成功地 实现更广泛的目标，即确定新的牛皮癣治疗途径并改变已批准药物的用途。